文献速递细菌感染、耐药与抗菌药物

CFTR调节剂对囊性纤维化患者铜绿假单胞菌感染的影响

Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis.
PubMed 文献 · J Infect Dis · 2024-01-01

研究从11例慢性定植的囊性纤维化患者的痰中分离出105株铜绿假单胞菌,比较使用elexacaftor-tezacaftor-ivacaftor或tezacaftor-ivacaftor治疗前及治疗后最长21个月菌株的表型与基因组变化。结果显示克隆谱系持续存在、未被其他菌株替代,经典慢性表型(如黏液型形态)持续存在,对临床相关抗生素的耐药性也未改变。

要点

  • 治疗后铜绿假单胞菌克隆谱系持续存在,未出现菌株替代。
  • 分离株中鉴定出可能在CFTR调节后肺部环境被正选择的常见突变基因。
  • 黏液型形态等经典慢性表型持续存在,对临床相关抗生素的耐药性未改变。

核心结论

  • 尽管CFTR调节剂有临床获益,铜绿假单胞菌克隆谱系仍持续存在,未来可能同样难以管理,尤其在合并晚期肺病的囊性纤维化患者中。

研究设计与样本

  • 从11例慢性定植的囊性纤维化患者的痰中分离105株铜绿假单胞菌,分别在基线及elexacaftor-tezacaftor-ivacaftor或tezacaftor-ivacaftor治疗后最长21个月采集。
  • 对分离株进行表型鉴定与比较基因组学分析。

主要发现

  • 治疗后铜绿假单胞菌克隆谱系持续存在,无证据显示被其他菌株替代。
  • 在患者分离株中鉴定出可能在CFTR调节后的肺环境被正选择的常见突变基因。
  • 经典慢性铜绿假单胞菌表型如黏液型形态持续存在。
  • 分离株对临床相关抗生素的耐药性与前相比保持不变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Pseudomonas aeruginosa is a multidrug-resistant pathogen causing recalcitrant pulmonary infections in people with cystic fibrosis (pwCF). Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been developed that partially correct the defective chloride channel driving disease. Despite the many clinical benefits, studies in adults have demonstrated that while P. aeruginosa sputum load decreases, chronic infection persists. Here, we investigate how P. aeruginosa in pwCF may change in the altered lung environment after CFTR modulation. METHODS: P. aeruginosa strains (n = 105) were isolated from the sputum of 11 chronically colonized pwCF at baseline and up to 21 months posttreatment with elexacaftor-tezacaftor-ivacaftor or tezacaftor-ivacaftor. Phenotypic characterization and comparative genomics were performed. RESULTS: Clonal lineages of P. aeruginosa persisted after therapy, with no evidence of displacement by alternative strains. We identified commonly mutated genes among patient isolates that may be positively selected for in the CFTR-modulated lung. However, classic chronic P. aeruginosa phenotypes such as mucoid morphology were sustained, and isolates remained just as resistant to clinically relevant antibiotics. CONCLUSIONS: Despite the clinical benefits of CFTR modulators, clonal lineages of P. aeruginosa persist that may prove just as difficult to manage in the future, especially in pwCF with advanced lung disease.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ledger EL, Smith DJ, Teh JJ, et al. Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis. J Infect Dis. 2024. PMID: 38442240. doi:10.1093/infdis/jiae051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。